Madison biopharmaceutical company Dianomi Therapeutics has raised $3 million in funding following a partnership with publicly traded drug company Ligand Pharmaceuticals. Dianomi announced Tuesday that Ligand invested $3 million in the startup in exchange for a royalty of two or three percent based on net sales for Dianomi’s first five products developed using its technology. Ligand will also provide […]
MADISON – Wisconsin’s early-stage health and life science firms and the Center for Technology Commercialization (CTC) received national attention for the state’s success over the past decade in landing competitive federal grants. Wisconsin ranked third after Oregon and Vermont in securing Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) funding from the […]
BioForward, Wisconsin’s state association representing over 200 biohealth member companies, announced three additions to this year’s Board of Directors. The board represents many facets of the state’s diverse biohealth industry and focuses on advocating for Wisconsin’s strengths in development of integrated health solutions and academic research.Newly elected Board Members for the 2019-21 term include: Jon […]
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced it has commenced a $200 million capital investment in its Biologics business to expand drug substance manufacturing capacity and drug product fill/finish capacity due to projected growth among existing and future […]
By the time he was diagnosed with metastatic melanoma, Luke Simons, now 83, had already watched his wife and his longtime business partner struggle with cancer. His wife had chemo for her breast cancer 20 years ago. His business partner with multiple myeloma died 5 years ago. “I was obviously aware of what it could […]
Fujifilm Cellular Dynamics Inc. (FCDI) plans to invest $21 million to create a facility in Madison’s University Research Park for manufacturing stem cell therapies that can be used as regenerative medicine — cells that can repair or rebuild a patient’s diseased or damaged tissue. Full Article available on Wisconsin State Journal
Agreement provides Sarepta with committed capacity and dedicated manufacturing slots for GMP-grade plasmid production for its micro-dystrophin Duchenne muscular dystrophy (DMD) gene therapy program, as well as plasmid capacity for future gene therapy programs Full Release available here
Read the full article from the University of Wisconsin – Madison here. A series of projects aimed at advancing the human-health and economic impact of biomanufacturing is already benefiting from a new University of Wisconsin–Madison institute aimed at making the state a Midwestern hub of the ongoing merger of pharmaceuticals, medical devices and cutting-edge tissue […]
Read the full press release here. MADISON, Wisc. – December 4, 2018 JangoBio is making substantial progress on several commercial and scientific fronts in its quest to develop stem cell-based therapies for hormone restoration. Building on a National Institutes of Health small business grant and an initial seed investment round, JangoBio is expanding its existing […]